A study has shown that plasmids use type IV CRISPR-Cas against competing plasmids, leading the researchers to suggest the method as a novel way to tackle multi-drug resistant bacteria.
List view / Grid view
Filter the results
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
Researchers have found that using antibiotics in combination with cannabidiol (CBD) enhanced their effect against Staphylococcus aureus bacteria.
Scientists suggest competence-blocking, ‘anti-evolution’ drugs could be administered alongside antibiotics to prolong the period before bacterial resistance emerges.
Researchers have developed a compound, called AB569, effective at combatting bacteria such as Pseudomonas aeruginosa and have revealed its mechanism of action.
A new monoclonal antibody has been discovered which disassociates bacterial biofilms and stops bacteria from entering into circulation has been tested in mice.
International collaboration has shown that compounds with metals in them show antibacterial activity against MRSA, E. coli and A. baumannii.
New T-cell discovery could lead to treatments for both bacterial infections and autoimmune conditions
A novel highly activated form of T cells could be suppressed to treat autoimmune conditions and activated in treating bacterial infections.
A new study has revealed how bacterial immune systems can be harmful for their hosts and why they are not found in all bacteria.
Drug Target Review’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines.
Researchers have developed a new combination of compounds called AB569 which has demonstrated success at fighting deadly pathgoens like Pseudomonas aeruginosa.
A new antibiotic compound has been identified by researchers who designed a machine-learning algorithm to screen millions of molecules.
Researchers have uncovered new antibiotics which prevent bacteria from multiplying, offering a strategy to fight infections.
A new technology developed by scientists combines small molecule screening methods with machine learning algorithms to identify novel antibiotics that inhibit ribosomes.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.